Drug Research

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

Bicycle Therapeutics has entered into a 15-year agreement with the UK Nuclear Decommissioning Authority (NDA) to utilize reprocessed uranium from nuclear reactors for the production of precision cancer therapies. Under the terms of the deal, announced by the UK government,...

Regeneron Pharmaceuticals is going ahead and investing more funds into gene editing, as it has announced a collaboration with Tessera Therapeutics in December 2025, so as to create an experimental program pertaining to rare liver and lung disease. At the...

The FDA has gone on to propose certain new policies in order to accelerate biosimilar drug development and at the same time also lower the cost pertaining to biosimilar agents when it comes to cancer as well as any...

Johnson & Johnson will be paying $3.05 billion so as to acquire Halda Therapeutics, thereby getting a novel cell death platform while at the same time also strengthening its prostate cancer franchise that’s built on Erleada. At the mainstay of the...

Drug development is entering an era of radical transformation as pharmaceutical companies embrace virtual trials and in silico methodologies to reimagine the clinical research process. These digital-first strategies tap into computational models, artificial intelligence, and patient-specific simulations to address...